Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers O > Headlines for Onyx Pharmaceuticals Inc. > News item |
Onyx maintained by Merrill at neutral
Onyx Pharmaceuticals Inc. was maintained by Merrill Lynch at a neutral rating following its submission of a New Drug Application on Monday for Sorafenib, in development with partner Bayer AG for the second-line treatment of metastatic renal cell carcinoma. Onyx shares on Monday dropped 35 cents, or 1.34% to $26.42 on volume of 1.3 million shares versus the three-month running average of 1.14 million.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.